Comparative Assessment of Different Anti-CD147/Basigin 2 Antibodies As a Potential Therapeutic Anticancer Target by Molecular Modeling and Dynamic Simulation

Overview

Journal Mol Divers

Date 2024 Apr 8

PMID 38587771

Authors

Nail Besli

Halil Ibrahim Bulut

Ilhan Onaran

Miguel Carmena-Bargueno

Horacio Perez-Sanchez

Affiliations

Soon will be listed here.

Abstract

Cluster of differentiation 147 (CD147) is an attractive target for anticancer therapy since it is pivotal in developing and progressing several of malignant tumors in the context of its high expression levels. Although anti-CD147 antibodies by different laboratories are designed for the Ig-like domains of CD147, there is a demand to provide priority among these anti-CD147 antibodies for developing of therapeutic anti-CD147 antibody before experimental validations. This study uses molecular docking and dynamic simulation techniques to compare the binding modes and affinities of nine antibody models against the Ig-like domains of CD147. After obtaining the model antibodies by homology modeling via Robetta, we predicted the CDRs of nine antibodies and the epitopes of CD147 to reach more accurate results for antigen affinity in molecular docking. Next, from HADDOCK 2.4., we meticulously handpicked the most superior model clusters (Z-Score: - 2.5 to - 1.2) and identified that meplazumab had higher affinities according to the success rate as the percentage of a scoring scale. We achieved stable simulations of CD147-antibody interaction. Our outcomes hold hypothetical importance for further experimental cancer research on the design and development of the relevant model antibodies.

References

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Riethdorf S, Reimers N, Assmann V, Kornfeld J, Terracciano L, Sauter G . High incidence of EMMPRIN expression in human tumors. Int J Cancer. 2006; 119(8):1800-10. DOI: 10.1002/ijc.22062. View

Baba M, Inoue M, Itoh K, Nishizawa Y . Blocking CD147 induces cell death in cancer cells through impairment of glycolytic energy metabolism. Biochem Biophys Res Commun. 2008; 374(1):111-6. DOI: 10.1016/j.bbrc.2008.06.122. View

Cui H, Guo T, Wang S, Zhao P, Dong Z, Zhang Y . Dimerization is essential for HAb18G/CD147 promoting tumor invasion via MAPK pathway. Biochem Biophys Res Commun. 2012; 419(3):517-22. DOI: 10.1016/j.bbrc.2012.02.049. View

Landras A, Reger De Moura C, Jouenne F, Lebbe C, Menashi S, Mourah S . CD147 Is a Promising Target of Tumor Progression and a Prognostic Biomarker. Cancers (Basel). 2019; 11(11). PMC: 6896083. DOI: 10.3390/cancers11111803. View

Maeda K, Kosugi T, Sato W, Kojima H, Sato Y, Kamimura D . CD147/basigin limits lupus nephritis and Th17 cell differentiation in mice by inhibiting the interleukin-6/STAT-3 pathway. Arthritis Rheumatol. 2015; 67(8):2185-95. DOI: 10.1002/art.39155. View

Krawczyk K, Buchanan A, Marcatili P . Data mining patented antibody sequences. MAbs. 2021; 13(1):1892366. PMC: 7971238. DOI: 10.1080/19420862.2021.1892366. View

Terstappen G, Reggiani A . In silico research in drug discovery. Trends Pharmacol Sci. 2001; 22(1):23-6. DOI: 10.1016/s0165-6147(00)01584-4. View

Song Y, DiMaio F, Wang R, Kim D, Miles C, Brunette T . High-resolution comparative modeling with RosettaCM. Structure. 2013; 21(10):1735-42. PMC: 3811137. DOI: 10.1016/j.str.2013.08.005. View

10.

Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R . SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018; 46(W1):W296-W303. PMC: 6030848. DOI: 10.1093/nar/gky427. View

11.

McGuffin L, Aldowsari F, Alharbi S, Adiyaman R . ModFOLD8: accurate global and local quality estimates for 3D protein models. Nucleic Acids Res. 2021; 49(W1):W425-W430. PMC: 8218196. DOI: 10.1093/nar/gkab321. View

12.

Pettersen E, Goddard T, Huang C, Couch G, Greenblatt D, Meng E . UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004; 25(13):1605-12. DOI: 10.1002/jcc.20084. View

13.

van Zundert G, Rodrigues J, Trellet M, Schmitz C, Kastritis P, Karaca E . The HADDOCK2.2 Web Server: User-Friendly Integrative Modeling of Biomolecular Complexes. J Mol Biol. 2015; 428(4):720-725. DOI: 10.1016/j.jmb.2015.09.014. View

14.

de Vries S, van Dijk M, Bonvin A . The HADDOCK web server for data-driven biomolecular docking. Nat Protoc. 2010; 5(5):883-97. DOI: 10.1038/nprot.2010.32. View

15.

Dunbar J, Deane C . ANARCI: antigen receptor numbering and receptor classification. Bioinformatics. 2015; 32(2):298-300. PMC: 4708101. DOI: 10.1093/bioinformatics/btv552. View

16.

Dunbar J, Krawczyk K, Leem J, Marks C, Nowak J, Regep C . SAbPred: a structure-based antibody prediction server. Nucleic Acids Res. 2016; 44(W1):W474-8. PMC: 4987913. DOI: 10.1093/nar/gkw361. View

17.

Roos K, Wu C, Damm W, Reboul M, Stevenson J, Lu C . OPLS3e: Extending Force Field Coverage for Drug-Like Small Molecules. J Chem Theory Comput. 2019; 15(3):1863-1874. DOI: 10.1021/acs.jctc.8b01026. View

18.

Xiang Z . Advances in homology protein structure modeling. Curr Protein Pept Sci. 2006; 7(3):217-27. PMC: 1839925. DOI: 10.2174/138920306777452312. View

19.

Hildebrand P, Rose A, Tiemann J . Bringing Molecular Dynamics Simulation Data into View. Trends Biochem Sci. 2019; 44(11):902-913. DOI: 10.1016/j.tibs.2019.06.004. View

20.

Helal M, Shouman S, Abdelwaly A, Elmehrath A, Essawy M, Sayed S . Molecular basis of the potential interaction of SARS-CoV-2 spike protein to CD147 in COVID-19 associated-lymphopenia. J Biomol Struct Dyn. 2020; 40(3):1109-1119. PMC: 7544927. DOI: 10.1080/07391102.2020.1822208. View